Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
24 hedge funds and large institutions have $2.19M invested in Bellicum Pharmaceuticals, Inc. in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
14% less funds holding
Funds holding: 28 → 24 (-4)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
51% less capital invested
Capital invested by funds: $4.48M → $2.19M (-$2.3M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$43.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.1K |
| 3 |
BlackRock
New York
|
+$602 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$52 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$97K |
| 2 |
LPL Financial
San Diego,
California
|
-$83K |
| 3 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$75K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.27K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$5.84K |
BLCM Hedge Fund Activity: Q4 2021 in Review
24 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2021, worth a combined $2.19M — down 51% from $4.48M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BLCM and 2 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $43.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $97K sold.
- 24 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2021, down from 28 in Q3 2021.
- Funds reported $2.19M of Bellicum Pharmaceuticals, Inc. stock for Q4 2021, down 51% quarter-over-quarter.
- 2 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2021 and 6 closed out, a net change of -4 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2021 was Virtu Financial, an estimated $43.9K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2021 was Citadel Advisors, an estimated $97K sold.
Based on aggregated 13F filings for Q4 2021.